ReviewCancer drug resistance (Alhambra, Calif.)2022

Transcriptional coactivator MED1 in the interface of anti-estrogen and anti-HER2 therapeutic resistance.

Gregory Bick et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.